Differentiating FSO and FSP approaches can better align definitions of models for CROs and sponsors.
Dr. Joachim Luithle
Advertisement
SVP, Head of Clinical Development Operations, Bayer
Articles by Dr. Joachim Luithle
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
2026 DIA Global Annual Meeting: What Drives Sponsors to Mixed Outsourcing Models and What the Transition Looks Like
2
2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now
3
Tapping the Global Potential of China’s Biotech Surge
4
ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure
5